Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone

Blood

Volumn 93, Issue 4, 1999, Pages 1287-1298

  Treon, Steven P ^b   Mollick, Joseph A ^b   Urashima, Mitsuyoshi ^b   Teoh, Gerrard ^b   Chauhan, Dharminder ^b   Ogata, Atsushi ^b   Raje, Noopur ^b   Hilgers, Joseph H M ^b   Nadler, Lee ^b   Belch, Andrew R ^b   Pilarski, Linda M ^b   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; DEXAMETHASONE; EPITOPE; ESTROGEN; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; PROGESTERONE;

ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033558252     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.4.1287     Document Type: Article

References (65)

1. Patton S, Gendler SJ, Spicer AP: The epithelial mucin, Muc1, of milk, mammary gland and other tissues. Biochim Biophys Acta 1241:407, 1995
2. Gendler SJ, Lancaster CA, Taylor-Papademetriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN, Wilson D: Molecular cloning and expression of human tumor associated polymorphic epithelial mucin. J Biol Chem 265:15286, 1990
3. Price MR, Rye PD, Petrakou E, Murray A, Brady K, et al: Summary report on the ISOBM TD-4 workshop: Analysis of 56 monoclonal antibodies against the Muc1 mucin. Tumor Biol 19:1, 1998
4. Petrakou E, Murray A, Price MR: Epitope mapping of anti-Muc1 mucin protein core monoclonal antibodies. Tumor Biol 19:21, 1998
5. Dai J, Allard WJ, Davis G, Yeung KK: Effect of desialylation on binding, affinity, and specificity of 56 monoclonal antibodies against Muc1 mucin. Tumor Biol 19:100, 1998
6. Hanisch FG: Specificity clusters of Muc1-reactive mouse monoclonal antibodies. Tumor Biol 19:111, 1998
7. Perey L, Hayes DF, Maimonis P, Abe M, O'Hara C, Kufe DW: Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma associated antigen. Cancer Res 52:2563, 1992
8. Brockhausen I, Yang JM, Burchell J, Whitehouse C, Taylor-Papademetriou J: Mechanisms underlying aberrant glycosylation of Muc1 mucin in breast cancer cells. Eur J Biochem 233:607, 1997
9. Delsol G, Stein H, Pulford KAF, Gatter KC, Erber WN, Zinne K, Mason DY: Human lymphoid cells express epithelial membrane antigen: Implications for diagnosis of human neoplasms. Lancet 2:1124, 1984
10. Pinkus GS, Kurtin PJ : Epithelial membrane antigen - A diagnostic discriminant in surgical pathology. Hum Pathol 16:929, 1985
11. Zotter S, Hageman PC, Lossnitzer A, Mooi WJ, Hilgers J: Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 11-12:55, 1988
12. Duperray C, Klein B, Durie BGM, Zhang X, Jourdan M, Poncelet P, Favier F, Vincent C, Brochier J. Lenoir G, Bataille R: Phenotypic analysis of human myeloma cell lines. Blood 73:566, 1989
13. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A: Expression of Muc1 on myeloma cells and induction of HLA unrestricted CTL against Muc1 from a multiple myeloma patient. J Immunol 153:2102, 1994
14. Al Saati T, Caveriviere P, Gorguet B, Delsol G, Gater KC, Mason DY: Epithelial membrane antigen in hematopoietic neoplasms. Hum Pathol 17:533, 1986
15. Delsol G, Al Saati T, Gatter KC, Gerdes J, Schwarting R, Caveriviere P, Rigal-Huguet F, Robert A, Stein H, Mason DY: Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Am J Pathol 130:59, 1988
16. Mark A, Mangkornkanok M: B-cell lymphoma marking only with anti-epithelial membrane antigen. Cancer 63:2152, 1989
17. Barnd DL, Lan M, Metzgar RS, Finn OJ: Specific, MHC unrestricted recognition of tumor associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86:7159, 1989
18. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ: Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 151:3693, 1993
19. Van de Wiel-Van Kemenade E, Ligtenberg MJL, de Boer AJ, Buijis F, Vos KL, Melief CJM, Hilkens J, Figdor CG: Episialin (Muc1) inhibits cytotoxic lymphocyte-target cell interaction. J immunol 151: 767, 1993
20. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM: Cancer-associated Muc1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 4:43, 1998
21. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC: The breast mucin Muc1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 56:4244, 1996
22. Tsarfaty I, Hareuveni M, Horev J, Zaretsky J, Weiss M, Jeltsch JM, Gernier JM, Lathe R, Keydar I, Wreschner DH: Isolation and characterization of an expressed hypervariable gene coding for a breast cancer associated antigen. Gene 93:313, 1990
23. Lancaster CA, Peat N, Duhig T, Wislon D, Taylor-Papademetriou J, Gendler SJ: Structure and expression of the human polymorphic epithelial mucin gene: An expressed VNTR unit. Biochem Biophys Res Commun 173:1019, 1990
24. Surveyor GA, Gendler SJ, Pemberton L, Das SK, Chakraborty I, Julian J, Pimental RA, Wegner CC, Dey SK, Carson DD: Expression and steroid hormonal control of Muc-1 in the mouse uterus. Endocrinology 136:3639, 1995
25. Hild-Petito S, Fazleabas AT, Julian J, Carson DD: Mucin (Muc-1) expression is differentially regulated in uterine luminal and glandular epithelia of the baboon. Biol Reprod 54:939, 1996
26. + monoclonal B lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 78:711, 1991
27. + peripheral blood cells expressing CD38, CD56, and monotypic immunoglobulin light chain. Blood 85:436, 1995
28. Kubagawa H, Vogler LB, Capra JD, Conrad ME, Lawton AR, Cooper MD: Studies on the clonal origin of multiple myeloma. J Exp Med 150:792, 1979
29. Billadeau D, Ahmann G, Greipp P, Van Ness B: The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 178:1023, 1993
30. Bakkus MHC, van Riet I, Van Camp B. Thielemann K: Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B-cell. Br J Haematol 87:68, 1994
31. Hitzler JK, Martinez-Valdez H, Bergsagel DB, Minden MD, Messner HA: Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood 78:1996, 1991
32. Okuno Y, Takahashi T, Suzuki A, Fukumoto M, Nakamura K, Fukui H, Koishihara Y, Ohsugi Y, Imura H: Acquisition of growth autonomy and tumorigenicity by an interleukin-6 dependent human myeloma cell line transfected with interleukin-6 cDNA. Exp Hematol 20:395, 1992
33. + cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient specific IgH rearrangements. Blood 89:1824, 1997
34. Pilarski LM, Gillitzer R, Zola H, Shortman K, Scollay R: Selective expression of CD45 (T200) antigens during human thymocyte differentiation. Eur J Immunol 19:589, 1988
35. Pilarski LM, Szczepek AJ, Belch AR: Deficient drug transporter function of bone marrow localized and leukemic plasma cells in multiple myeloma. Blood 90:3751, 1997
36. Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, Pilarski LM: A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in-situ RT-PCR. Blood 92:2844, 1998
37. Hokland P, Hokland M, Heron I: An improved technique for obtaining E rosettes with human lymphocytes and its use for B cell purification. J Immunol Methods 13:175, 1976
38. + selected cells from peripheral blood. Blood 89:3967, 1997
39. Goldmacher VS, Bourret LA, Levine BA, Rasmussen RA, Pourshadi M, Lambert JM, Anderson KC: Anti-CD-38-blocked ricin: An immunotoxin for the treatment of multiple myeloma. Blood 84:3017, 1994
40. Stevenson FK, Bell AJ, Cusack R, Hamblin TJ, Slade CJ, Spellerberg MB, Stevenson GT: Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 77:1071, 1991
41. Huang YW, Richardson JA, Vitetta ES: Anti-CD54 (ICAM-1) has antitumour activity in SCID mice with human myeloma cells. Cancer Res 55:610, 1995
42. Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T: Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood 90:3179, 1997
43. Vooijs WC, Schuurman HJ, Bast EJ, deGast GC: Evaluation of CD38 as a target for immunotherapy in multiple myeloma. Blood 85:2282, 1995
44. Voojis WC, Post J, Wijdenes J, Schuurman HJ, Bolognesi A, Polito L, Stirpe F, Bast EJ, deGast GC: Efficacy and toxicity of plasma cell reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins. Cancer Immunol Immunother 42:319, 1996
45. - progenitor cells. Blood 77:1218, 1991
46. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ: Humoral immune response against a tandem repeat epitope of human mucin Muc-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54:2856, 1994
47. Gourevitch MM, von Mensdorff-Pouilly S, Litvinov SV, Kenemans P, van Kamp GJ, Verstraeten AA, Hilgers J: Polymorphic epithelial mucin (Muc-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 72:934, 1995
48. Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, Jamieson G, Pietersz G, Tait B, Broadbent R, Thynee G, McKenzie IF: Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 100:2783, 1997
49. Gilewski T, Adluri R, Zhang S, Houghton A, Norton L, Livingston P: MUC-1 keyhole limpet hemocyanin (KLH) conjugate plus QS-21 vaccination of high risk breast cancer patients with no evidence of disease. Proc Am Soc Clin Oncol 16: A1569, 1997 (abstr)
50. Graham RA, Burchell JM, Beverley P, Taylor-Papademetriou J: Intramuscular immunization with Mucl cDNA can protect C57 mice challenged with Muc1-expressing syngeneic mouse tumour cells. Int J Cancer 65:664, 1996
51. Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, Kantor JA: Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified Mucl gene and the murine T-cell costimulatory molecule B7. J Immunother 20:38, 1997
52. Zhang S, Graeber LA, Helling F, Ragupathi G, Adluri S, Lloyd KO, Livingston P: Augmenting the immunogenicity of synthetic Muc1 peptide vaccines in mice. Cancer Res 56:3315, 1996
53. Gong J, Chen D, Kashiwaba M, Kufe D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3:558, 1997
54. Friedmann EL, Hayes DF, Kufe DW: Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res 46:5189, 1986
55. Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, Stewart JSW, Mason P, Lambert HE, Epenetos AA: Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 68:403, 1993
56. Cao Y, Karsten U, Hilgers J: Immunohistochemical characterization of a panel of 56 antibodies with normal human, small intestine, colon, and breast tissues. Tumor Biol 19:88, 1998
57. Gregoretti MG, Gottardi D, Ghia P, Bergui L, Merico F, Marchisio PC, Caligaris-Cappio F: Characterization of bone marrow stromal cells from multiple myeloma. Leuk Res 18:675, 1994
58. Carter A, Merchav S, Silvan-Draxler I, Tatarsky I: The role of interleukin-1 and tumor necrosis factor alpha in human multiple myeloma. Br J Haematol 74:424, 1990
59. Lu ZY, Bataille R, Poubelle P, Rapp MJ, Harousseau JL, Klein B: An interleukin 1 receptor antagonist blocks the IL-1 induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma. Stem Cells 113:28, 1995
60. Dittel BN, McCarthy JB, Wayner EA, LeBien TW: Regulation of human B-cell precursor adhesion to bone marrow stromal cells by cytokines that exert opposing effects on the expresson of vascular cell adhesion molecule-1. Blood 81:2272, 1993
61. Yang J, Xu Y, Zhu C, Hagan MK, Lawley T, Offerman MK: Regulation of adhesion molecule expression in Kaposi's Sarcoma cells. J Immunol 152:361, 1994
62. Rettig MB, MA HJ, Vescio RA, Pold M, Schiller G, Belson D, Savage A, Nishikubo C, Wu C, Fraser J, Said JW, Berenson J: Kaposi's sarcoma associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276:1851, 1997
63. Offerman MK, Lin JC, Mar EC, Shaw R, Yang J, Medford RM: Antioxidant sensitive regulation of inflammatory response genes in Kaposi's Sarcoma cells. J AIDS Hum Retroviruses 13:1, 1996
64. Treon SP, Anderson KC: Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. Cun Opin Hematol 5:42, 1998
65. Brady ME, Sartiano GP, Rosenblum SL, Zaglama NE, Bauguess CT: The pharmacokinetics of single high doses of dexamethasone in cancer patients. Eur J Clin Pharm 32:593, 1987